A study in patients with a sudden blood clot in the leg, to remove this clot using the Indigo™ aspiration system.

Critères de participation
1. Be 18 years of age or older. 2. Have a confirmed diagnosis of a blocked artery in the leg, starting from the common iliac artery or lower, with at least 2 cm of open artery before the blockage. 3. Have a recent occlusion (blockage), with symptoms that appeared within the last 14 days. 4. Be in one of the following categories according to the Rutherford classification for acute limb ischemia (ALI): category I, IIa, or IIb (which means reduced but still recoverable circulation). 5. Treatment must begin with the Indigo aspiration system, using computer-assisted technology called CAVT. 6. Informed consent must be obtained, either directly from the patient or from their legal representative, according to the ethics committee rules. 7. A participant already enrolled may participate again if they develop a new occlusion in the other leg, at least 30 days after the first treatment, provided they still meet all eligibility criteria. (BASEC)

Critères d'exclusion
1. The patient has a life expectancy of less than one year. 2. The blood vessel to be treated is very small (less than 2 mm in diameter). 3. The clot is located in the aorta or an isolated deep artery. 4. The patient has had a major amputation (near the foot) in the affected leg. 5. The patient has had a minor amputation in the affected leg in the last 6 months that is not fully healed or does not allow walking. 6. The ischemia (lack of blood) is due to dissection, inflammation of the vessels (vasculitis), or trauma (accident or injury), including if it is due to medical treatment. 7. The clot is located in a venous bypass (such as a graft using the saphenous vein). 8. The patient has already been treated for this episode with medications to dissolve the clot or another intervention (surgical or endovascular) before being included in the study. 9. The patient is pregnant. 10. The patient is allergic or cannot receive the iodinated contrast agent used for imaging and cannot receive preventive medication. 11. The patient has medical, psychological, or behavioral issues that, in the physician's opinion, prevent proper consent or make participation in the study difficult (such as adhering to follow-up appointments), or that could bias the study results. 12. The patient is already participating in another study with an experimental drug or device, which could influence the results. (Follow-up studies for products already available on the market do not count as experimental.) (BASEC)